Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 11/20 | 0.83 |
| ▸ | CYP1A1 | P04798 | 10/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.82 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.68 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368933 | 1.00 | CYP1B1 (0.83) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13479662 | 0.93 | RAB9A (0.88) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17233302 | 0.91 | CYP1A1 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL196639 | 0.90 | PFKFB3 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29458617 | 0.90 | PFKFB3 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9503680 | 0.90 | CYP1B1 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL979408 | 0.90 | CYP1B1 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL196640 | 0.90 | PFKFB3 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1604140 | 0.87 | RAB9A (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29600034 | 0.87 | RAB9A (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-54110294-A | — | — | None | — | — | JP | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-1993019047-A1 | TETRAHIDROPYRIDINYL (3/4) SUBSTITUED OXIMES HAVING SIGMA RECEPTOR AFFINITY AND THEIR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | WARNER-LAMBERT COMPANY (US) | 1993-09-30 | — | — | WO | disclosed |
| US-5208343-A | Antidepressants, antiinflammatory | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| JP-S54110294-A | NEW PHOTO-CROSSLINKABLE POLYMERIC COMPOUND AND ITS PREPARATION | AGENCY OF IND SCIENCE & TECHNOL | 1979-08-29 | — | — | JP | disclosed |
| US-3991197-A | ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1976-11-09 | — | — | US | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP1B1 780/4885CYP1A1 656/4885CYP1A2 795/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP1B1 747/4885CYP1A1 649/4885CYP1A2 792/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP1B1 604/4885CYP1A1 625/4885CYP1A2 655/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP1B1 604/4885CYP1A1 625/4885CYP1A2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.